BSXBoston Scientific exhibits strong fundamental performance and benefits from positive thematic trends in healthcare technology. Technical indicators show some mixed signals, suggesting a 'Buy' rating with a watchful approach to short-term price movements.
Boston Scientific is well-positioned in several key thematic areas, including medical device innovation, aging populations, and advancements in minimally invasive procedures.
Boston Scientific demonstrates solid financial health, with consistent revenue growth, healthy profitability, and a manageable debt level. Strong free cash flow generation supports its operations and potential for future investment.
The stock is in a generally bullish trend, trading above key moving averages. However, some oscillators are approaching overbought territory, suggesting potential for short-term consolidation.
| Factor | Score |
|---|---|
| Healthcare Innovation & Technology | 90 |
| Aging Population | 85 |
| Minimally Invasive Procedures | 88 |
| Emerging Markets Growth | 70 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 80 |
| Growth | 88 |
| Balance Sheet Health | 85 |
| Cash Flow | 82 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 70 |
| Volume Confirmation | 75 |
| Support & Resistance | 60 |
Consistent EPS Beats
The company has exceeded earnings per share (EPS) estimates for the last 8 consecutive quarters, with an average surprise of +7.57%, indicating robust operational execution and forecasting accuracy.
Favorable P/E to Growth Ratio
The Price-to-Earnings (P/E) ratio of 63.22 is high, but the company's projected earnings growth suggests a Price/Earnings to Growth (PEG) ratio that may be attractive if growth materializes.
High Trailing P/E Ratio
The trailing P/E ratio of 63.22 is significantly higher than the average of many mature companies, indicating that the stock may be trading at a premium and is sensitive to future earnings performance.
Slowing Quarterly Revenue Growth
Quarterly revenue growth has shown variability, with Q1 2025 at 14.5% and Q4 2024 at 12.4%, following a more substantial 2024 annual growth, which might suggest a deceleration in top-line expansion.
July 2025
23
Next Earnings Date
H: $0.75
A: $0.71
L: $0.70
H: 5.07B
A: 4.96B
L: 4.80B
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
123.03 USD
The 39 analysts offering 1 year price forecasts for BSX have a max estimate of 140.00 and a min estimate of 98.34.